Gilead Profit Tops Estimates as Hepatitis C Drug Sales Surge
Gilead Sciences Inc., maker of the hepatitis C drugs Sovaldi and Harvoni, posted second-quarter profit that topped analysts’ estimates as revenue surged. Gilead raised its sales forecast for the year.